EGFR and non-small cell lung carcinoma: On the other hand, the ADAURA trial evaluated osimertinib in resected stage IB–IIIA EGFR-mutant NSCLC, demonstrating a substantial disease-free survival advantage (22.1 vs. 14.9 months) [46].